(HealthDay News) — Among postmenopausal women receiving letrozole as adjuvant therapy for breast cancer, a telephone-based weight loss intervention was effective in promoting weight loss, according to research published online in the Journal of Clinical Oncology.
Pamela J. Goodwin, MD, of Mount Sinai Hospital in Toronto, and colleagues conducted a multicenter, randomized trial of mail delivery of general health information alone, or in combination with a telephone-based lifestyle intervention, in women receiving adjuvant letrozole for breast cancer.
The lifestyle intervention included recommendations for achieving weight loss through diet and physical activity.
The researchers found that women in the intervention group achieved significantly greater mean weight loss than those in the comparison group at 6 months (4.3 kg vs. 0.6 kg) and at 24 months (3.1 kg vs. 0.3 kg). This finding occurred consistently across strata for BMI (24 to less than 30 kg/m2 vs. 30 kg/m2 or greater).
The greatest weight loss occurred in those with higher levels of moderate-intensity physical activity at baseline, or improvement in quality of life.
No difference in hospitalization rates or medical events was observed between the groups.
“[The article] that accompanies this editorial adds to the growing body of evidence supporting the benefits of weight loss interventions in overweight breast cancer survivors,” the author of an accompanying editorial wrote.
Novartis Pharmaceuticals funded the study. Several authors disclose financial ties to pharmaceutical companies, including Novartis.
- Goodwin PJ, Segal RJ, Vallis M et al. Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. J Clin Oncol. 2014;doi:10.1200/JCO.2013.53.1517.
- Irwin ML. Weight Loss Interventions and Breast Cancer Survival: The Time Is Now. J Clin Oncol. 2014;doi:10.1200/JCO.2014.56.4583.